Sanctuary Advisors LLC Acquires Shares of 80,075 Inogen, Inc. (NASDAQ:INGN)

Sanctuary Advisors LLC bought a new position in shares of Inogen, Inc. (NASDAQ:INGN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 80,075 shares of the medical technology company’s stock, valued at approximately $651,000. Sanctuary Advisors LLC owned about 0.34% of Inogen as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently made changes to their positions in INGN. Meeder Asset Management Inc. bought a new stake in Inogen during the 2nd quarter worth about $30,000. PNC Financial Services Group Inc. increased its holdings in shares of Inogen by 2,918.3% in the fourth quarter. PNC Financial Services Group Inc. now owns 7,908 shares of the medical technology company’s stock valued at $43,000 after purchasing an additional 7,646 shares in the last quarter. CWM LLC increased its holdings in shares of Inogen by 2,185.9% in the second quarter. CWM LLC now owns 6,629 shares of the medical technology company’s stock valued at $54,000 after purchasing an additional 6,339 shares in the last quarter. Susquehanna Fundamental Investments LLC bought a new position in Inogen in the 1st quarter worth approximately $81,000. Finally, Pitcairn Co. acquired a new position in Inogen during the 1st quarter worth $86,000. 89.94% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the company. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a research note on Wednesday, August 7th. StockNews.com upgraded Inogen from a “sell” rating to a “hold” rating in a research report on Tuesday, August 13th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $7.00.

Inogen Stock Performance

INGN opened at $9.18 on Tuesday. The company has a fifty day moving average price of $11.02 and a two-hundred day moving average price of $9.12. The firm has a market capitalization of $216.44 million, a PE ratio of -2.22 and a beta of 1.04. Inogen, Inc. has a 52 week low of $4.13 and a 52 week high of $13.33.

Inogen (NASDAQ:INGN) last released its quarterly earnings data on Tuesday, August 6th. The medical technology company reported ($0.24) EPS for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.31. The business had revenue of $88.77 million during the quarter, compared to the consensus estimate of $82.50 million. Inogen had a negative return on equity of 45.37% and a negative net margin of 28.30%. The firm’s revenue was up 6.1% on a year-over-year basis. During the same quarter in the prior year, the company posted ($0.42) earnings per share. Equities analysts forecast that Inogen, Inc. will post -1.92 EPS for the current year.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.